테고사이언스
191420KOSDAQ기초 의약물질 제조업51.3 / 100
Reference Date: 2026-06-10
Company InformationBased on 2025 Annual Report
Business Overview
Tegos Science specializes in developing and producing cell therapy products using advanced cell culture technology, alongside offering contract manufacturing, consulting, and quality management services. The company has commercialized a 3D cultured skin model, NeoDerm®, for animal alternative testing and drug screening. The global cell therapy market is projected to grow from $4.2 billion in 2023 to $7.8 billion by 2028, with Tegos holding three approved cell therapy products in South Korea, including treatments for burns, diabetic foot ulcers, and wrinkle improvement.
Number of Employees
40people
Average Salary
48.0M KRW
Score Calculation Basis
Detailed Financial Score
Lower than industry avg (good)
2.3x industry avg (excellent)
7.2x industry avg (risky)
Avg ▼12.6% (2-year basis)
Avg ▼93.1% (2-year basis)
Avg ROE -4.0% (declining, 3yr)
Detailed News Sentiment
- Positive테고사이언스, 제약영업사 피앤피팜 인수…'칼로덤' 영업 확대
테고사이언스의 피앤피팜 인수로 화상 치료 제품 칼로덤의 영업망 확장 및 연구개발 강화로 성장 기회 확대.
- Positive테고사이언스 "피앤피팜 주식 37억원어치 취득…지분율 95%"
테고사이언스의 피앤피팜 주식 취득으로 지분율이 상승하여 기업의 경영 지배력 강화와 시너지 효과 기대.
Detailed Momentum
Near 52w low (0%, downtrend)
1m -42.12% (strong drop)
Volume surge
Detailed Disclosure
- Neutral타법인주식및출자증권취득결정(자율공시)2026-05-19
- Neutral분기보고서 (2026.03)2026-05-14
